3,5,2′,4′-Tetrahydroxychalcone, a new non-purine xanthine oxidase inhibitor

Chemico-Biological Interactions

Volumn 189, Issue 3, 2011, Pages 161-166

  Niu, Yanfen ^a   Zhu, Huajie ^b   Liu, Jia ^a   Fan, Huafang ^b,c   Sun, Ling ^a   Lu, Wei ^a   Liu, Xu ^a   Li, Ling ^a  

^a KUNMING MEDICAL UNIVERSITY   (China)

^b KUNMING INSTITUTE OF BOTANY   (China)

^c HUNAN UNIVERSITY   (China)

Author keywords

3,5,2 ,4 Tetrahydroxychalcone; Hyperuricemia; Uric acid; Xanthine oxidase

Indexed keywords

3,5,2'4' TETRAHYDROXYCHALCONE; ALLOPURINOL; UNCLASSIFIED DRUG; URIC ACID; XANTHINE OXIDASE; XANTHINE OXIDASE INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HYPERURICEMIA; IC 50; MALE; MOUSE; NONHUMAN; SINGLE DRUG DOSE; TOXICITY TESTING; TREATMENT RESPONSE; URIC ACID BLOOD LEVEL;

ANIMALS; CHALCONE; CHALCONES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HYDROXYLATION; HYPERURICEMIA; KINETICS; MICE; URIC ACID; XANTHINE OXIDASE;

MUS;

EID: 79551529506     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2010.12.004     Document Type: Article

References (26)

1. V. Massey, P.E. Brumby, H. Komai, and H. Palmer Studies on milk xanthine oxidase, some spectral and kinetic properties J. Biol. Chem. 244 1969 1682 1691
2. K.T. Scott, and C.A. Agudelo Gout J. Am. Med. Assoc. 289 2003 2857 2860
3. N. Lawrence Edwards The role of hyperuricemia and gout in kidney and cardiovascular disease Clev. Clin. J. Med. 75 Suppl. 5 2008 S13 S16
4. T. Nakagawa, H. Hu, S. Zharikov, K.R. Tuttle, R.A. Short, O. Glushakova, X. Ouyang, D.I. Feig, E.R. Block, J. Herrera-Acosta, J.M. Patel, and R.J. Johnson A causal role for uric acid in fructose-induced metabolic syndrome Am. J. Physiol. Renal Physiol. 290 2006 F625 631
5. K. Murata, K. Nakao, N. Hirata, K. Namba, T. Nomi, Y. Kitamura, K. Moriyama, T. Shintani, M. Iinuma, and H. Matsuda Hydroxychavicol: a potent xanthine oxidase inhibitor obtained from the leaves of betel, Piper betle J. Nat. Med. 63 2009 355 359
6. B. Hammer, A. Link, A. Wagner, and M. Bohm Hypersensitivity syndrome during therapy with allopurinol in asymptomatic hyperuricemia with a fatal outcome Dtsch. Med. Wochenschr. 126 2001 1331 1334
7. P.O. Fritsch, and A. Sidoroff Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis Am. J. Clin. Dermatol. 1 2000 349 360
8. H. Horiuchi, M. Ohta, S. Nishimura, H. Kaneko, Y. Kasahara, T. Ohta, and K. Komoriya Allopurinol induces renal toxicity by impairing pyrimidine metabolism in mice Life Sci. 66 2000 2051 2070
9. M.K. Reinders, and T.L.T.A. Jansen Management of hyperuricemia in gout: focus on febuxostat Clin. Interv. Aging 5 2010 7 18
10. P.I. Hair, P.L. McCormack, and G.M. Keating Febuxostat Drugs 68 2008 1865 1874
11. S. Shibata Anti-tumorigenic chalcones Stem Cells 12 1994 44 52
12. H. Haraguchi, H. Ishikawa, K. Mizutani, Y. Tamura, and T. Kinoshita Antioxidative and superoxide scavenging activities of retrochalcones in Glycyrrhiza inflate Bioorg. Med. Chem. 6 1998 339 347
13. S.F. Nielsen, M. Larsen, T. Boesen, K. Schonning, and H. Kromann Cationic chalcone antibiotics. Design, synthesis, and mechanism of action J. Med. Chem. 48 2005 2667 2677
14. J.C. Onyilagha, B. Malhotra, M. Elder, C.J. French, and G.H. Neil Towers Comparative studies of inhibitory activities of chalcones on tomato ringspot virus (ToRSV) Can. J. Plant. Pathol. 19 1997 133 137
15. H. Tanaka, S. Nakamura, K. Onda, M. Tazaki, and T. Hirano Sofalcone, an anti-ulcer chalcone derivative, suppresses inflammatory crosstalk between macrophages and adipocytes and adipocyte differentiation: implication of heme-oxygenase-1 induction Biochem. Biophys. Res. Commun. 381 2009 566 571
16. E. Amor, I. Villase, M. Ghayur, A. Gilani, and M. Choudhary Prolyl endopeptidase inhibitors from Syzygium samarangense (Blume) Merr. & LM Perry Z. Naturforsch. C 59c 2004 86 92
17. F. Borges, E. Fernandez, and F. Roleira Progress towards the discovery of Xanthine oxidase inhibitors Curr. Med. Chem. 9 2002 195 217
18. M.R. Rashidi, and H. Nazemiyeh Inhibitory effects of flavonoids on molybdenum hydroxylases activity Expert Opin. Drug Metab. Toxicol. 6 2010 133 152
19. T.G. Liao, Q.A. Wang, W.Q. Fang, and H.J. Zhu Studies on the synthesis of novel chalcone and biological activity Chin. J. Org. Chem. 5 2006 685 689
20. L.D. Kong, Y. Zhang, X. Pan, R.X. Tan, and C.H.K. Cheng Inhibition of xanthine oxidase by liquiritigenin and isoliquiritigenin isolated from Sinofranchetia chinensis Cell Mol. Life Sci. 57 2000 500 505
21. B. Stavric, S. Clayman, R.E. Gradd, and D. Hebert Some in vivo effects in the rat induced by chlorprothixene and potassium oxonate Pharmacol. Res. Commun. 7 1975 117 124
22. I.H. Hall, J.P. Scoville, D.J. Reynolds, R. Simlot, and P. Duncan Substituted cyclic imides as potential anti-gout agents Life Sci. 46 1990 1923 1927
23. J.J. Carroll, J. Coburn, R. Douglas, and A.L. Babson A simplified alkaline phosphotungstate assay for uric acid in serum Clin. Chem. 17 1971 158 160
24. J.M. Pauff, and R. Hille Inhibition Studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin J. Nat. Prod. 72 2009 725 731
25. W.J. Johnson, B. Stavric, and A. Chartrand Uricase inhibited in the rat by s-triazines: an animal model for hyperuricemia and hyperuricosuria Proc. Soc. Exp. Biol. Med. 131 1969 8 12
26. Y. Osada, M. Tsuchimoto, H. Fukushima, K. Takahashi, S. Kondo, M. Hasegawa, and K. Komoriya Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents Eur. J. Pharmacol. 241 1993 183 188